Understanding the repopulating characteristics of human sessing more mature cell surface markers, comprise the hematopoietic stem/progenitor cell fractions is crucial for human component of mouse spleen and peripheral blood, predicting their performance after transplant into high-risk indicating that development proceeds from primary hematopatients following high-dose therapy. We report that human poietic sites to the periphery. Repopulation of secondary umbilical cord blood cells, 78% to 100% of which express recipients with human cells by BM from primary recipients the hematopoietic progenitor cell surface marker CD34, can demonstrates the maintenance of substantial proliferation consistently engraft, develop, and proliferate in the hematocapacity of the input precursor population. These data sugpoietic tissues of sublethally irradiated NOD/LtSz-scid/scid gest that the cells capable of initiating human cell enmice. Engraftment and development of CD34 " cells is not graftment (SCID-repopulating cells) are contained in the dependent on human growth factor support. CD34 " cells CD34 " cell fraction, and that this mouse model will be useful home to the mouse bone marrow (BM) that becomes the for assaying the developmental potential of other rare huprimary site of human hematopoietic development conman hematopoietic cell fractions in vivo. taining myeloid, lymphoid, erythroid, and CD34 " progenitor ᭧ 1997 by The American Society of Hematology. populations. Myeloid, and in particular lymphoid cells possuch as umbilical cord blood (CB) and mobilized peripheral colonies of erythroid, granulocyte/monocyte, and macro-Canada; and The Jackson Laboratory, Bar Harbor, ME. phage precursors over an extended time period in a defined,
M blood (PB) progenitor cells are currently under investigation.
AMMALIAN HEMATOPOIESIS is a developmental progression that proceeds from a small pool of Additionally, the possibility of expanding primitive stem unique progenitor cells with long-term, multilineage potencells ex vivo is potentially a clinically useful strategy that tial to larger populations with more limited potential, to the is actively being pursued in many laboratories. 8,9 A major mature blood cells found in the circulation. 1 Characterization concern with a number of these approaches is that the quality and quantification of these progenitor pools is fundamental and number of stem cells in these populations are largely to our understanding of this developmental sequence and is unknown. Consequently an experimental transplantation of great importance for human hematopoietic cell transassay that could measure the repopulating potential of variplantation biology. Much of our understanding of the develous human precursor fractions would be invaluable in furopment and regulation of the mammalian hematopoietic systhering our understanding of these primitive hematopoietic tem, including stem and progenitor cell potential and lineage progenitors. relationships, has been derived from work in the mouse. 1 In Over the past decade, several groups have transplanted particular, the transplantation assays available in the mouse hematopoietic precursors into different mouse mutants in an model have been instrumental in defining and characterizing attempt to develop a reproducible transplantation assay. In the most primitive elements of the hematopoietic system;
the SCID/hu model developed by McCune et al, 10 a human namely the long-term repopulating stem cell endowed with hematopoietic microenvironment is created by implanting the potential to provide long-term, multilineage hematopoiefragments of human fetal thymus and liver 10 or bone 11 into sis following transplantation into appropriate recipients. [2] [3] [4] severe combined immunodeficiency disorder (C.B-17-scid/ As comparable experimental transplantation assays do not scid; SCID) mice. Hematopoietic precursor populations subexist for human hematopoietic precursors, little is known about human long-term repopulating stem cells. The large majority of studies reported to date have attempted to extrap-National Jewish Center (NJC; Denver, CO) from breeding pairs sequently injected into these transplanted fetal tissues have kindly provided by Leonard D. Shultz. The breeding colony is been shown to proliferate and differentiate. [11] [12] [13] This has been housed in a restricted barrier facility and the experimental animals a particularly useful model for examining lymphocyte develwere maintained in microisolator cages on laminar flow racks in a opment in vivo. 10, 12 However few of the experimental cells clean experimental room. Mice were maintained on an irradiated, in these models seed the mouse bone marrow (BM) or the sterile diet of Picolab Mouse Diet 20 (PMI Feeds, Inc, St Louis, peripheral hematopoietic tissues; instead they are generally MO) and given autoclaved, acidified water.
restricted to the fetal explants. Models where human hemato-NOD/SCID mouse manipulations. All animal experiments were poietic cells are transplanted intravenously into sublethally approved by the Animal Care Committees of the NJC and the Uniirradiated mice may more closely recapitulate the ability of versity of Colorado Health Sciences Center. Immediately before cell transplantation 8-to 10-week-old NOD/SCID mice were injected particular human progenitors to home to primary hematopoiintraperitoneally (IP) with 250 mL of phosphate-buffered saline etic sites as well as reflect their in vivo developmental poten-(PBS) that contained 50 mL of reconstituted anti-asialo GM1 (Wako tial. Such systems have been developed in beige/nude/x-Chemicals, Inc, Richmond, VA). Identical treatments were perlinked immunodeficiency (BNX) [14] [15] [16] [17] and SCID 18-22 mice. formed on days 5 and 11 postinfusion of experimental cells. Mice Unfractionated adult BM, 14, 17, 19, 20 PB, 17, 20 and CB, 21 15, 16 have shown that when BM-or PBcells from the cell fraction being tested. In cases where secondary derived CD34 / progenitor cells were cotransplanted with transplants were performed, BM cells were prepared from primary recipients as described below, pelleted 4 minutes at 720g and resus-human interleukin-3 (IL-3)-expressing stromal cells into pended at 1.6 to 2.4 1 10 6 /mL in IMDM/10% FBS. Secondary BNX mice, they could be maintained and generate cells of recipients each received 4 to 6 1 10 6 cells of the mouse/human cell both the myeloid and lymphoid lineages. In most of these suspension. For the duration of selected experiments, mice were studies, high frequencies of engraftment or hematopoietic injected IP three times per week with 250 mL PBS/5% FBS condevelopment have depended on treatment of mice with hutaining 10 mg each of the human growth factors IL-3, granulocyteman cytokines or cotransplant with stromal cells engineered macrophage colony-stimulating factor (GM-CSF), and stem cell facto produce human cytokines. In studies where growth factors tor (SCF) (Amgen, Inc, Thousand Oaks, CA). After infusion of cells, were not used, 17, 21, 22 high numbers of unfractionated input mice were maintained in a HEPA-filtered isolator (Isotec, Bichester, cells were required and/or engraftment was infrequent. 17 UK) within an ultraclean barrier room for the duration of the experi-Recently, the scid mutation has been backcrossed onto the ment. The mice were killed in a CO 2 chamber at predetermined time nonobese diabetic (NOD/Lt) mouse background. In addition points. Blood was collected into heparinized tubes from pools formed in the chest cavity after the dorsal aorta was severed. Femurs to lacking T-and B-cell function, the resulting NOD/LtSzand tibia were collected and aspirated with PBS/5% FBS to liberate scid/scid (NOD/SCID) mice exhibit low natural killer cell BM cells. Cell suspensions were then filtered through sterile 70 mm activity, are defective in macrophage function, and lack he-Nitex to get rid of clumps and debris. The spleen and thymus (if molytic complement. 23 NOD/SCID mice have shown impresent) from each mouse was harvested and strained through sterile proved engraftment over the SCID model when transplanted 70 mm Nitex into PBS/5% FBS to collect cells. with unfractionated human spleen cells, 24 BM leukocytes, 25 CB CD34 / cell enrichment. Blood was aseptically aspirated PB mononuclear cells, 26 and unfractionated CB cells. 27, 28 from placenta and umbilical CB veins immediately following normal
The improved ability to transplant human hematopoietic cells obstetrical deliveries at University Hospital (Denver, CO) and placed into NOD/SCID mice provides the foundation to develop a into blood bags containing an anticoagulant (citrate, phosphate, dexrepopulation assay for primitive human cells. Although previtrose, adenine-1). Samples were processed within 8 hours of collecous work has suggested that the cell capable of initiating the NH 4 Cl, 12 mmol/L NaHCO 3 , 0.1 mmol/L EDTA) at room tempera-MATERIALS AND METHODS ture for 2 minutes followed by washing with PBS/0.1% bovine serum albumin (BSA) and centrifugation at 500g for 5 minutes. To prevent Mice. Experimental NOD/SCID mice were obtained from a breeding colony established at the Biological Resource Center at the nonspecific antibody binding, cells were resuspended for 20 minutes AID Blood 0030 / 5h38$$$581 08-14-97 10:29:10 blda WBS: Blood
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From at 4ЊC in an antibody against F c receptor (24.G2 30 ). Cells were 72ЊC, 45 seconds, and a final primer extension at 72ЊC for 7 minutes. Specific primers included: 5-aaggataccacaataagctgc-3, and 5-washed and pelleted before being resuspended in 5 mg/1 1 10 6 cells of the appropriate antibody and incubated for 20 minutes at 4ЊC. ggtttgtggagactggcac-3. This primer set yields a 156-bp product from the 3 untranslated region of the human Cart-1 gene and fails to Cells were then washed in PBS/0.1% BSA and resuspended in 0.5 mL of the same buffer. Two-or three-color flow cytometry was amplify a product from mouse genomic DNA. 33 Positive and negative controls for human specificity of the primers included using performed with a Coulter EPICS XL flow cytometer (Coulter, Hialeah, FL) using the software provided. Cells from a control mouse template extracted from either 1,000 human PB white cells or 1,000 mouse BM cells, respectively. As a control for the presence of were stained with the same antibodies as a negative control. Appropriate isotype controls were also run for each fraction analyzed. Anti-sufficient DNA template, parallel PCR reactions were performed on each sample using primers specific for b-actin. This primer set human (hu) CD45-fluorescein isothiocyanate (FITC) and antimouse (mu) CD45-phycoerythrin (PE) were used to identify the ratio of consisted of: 5-aaggccaaccgcgagaagat-3 and 5-tcggtgaggatcttcatgag-3, that amplifies a 249-bp fragment from control genomic human:mouse leukocytes. Specific subsets of human cells were quantified by gating on hu CD45-PerCP / cells and then assessing DNA. 34 The reaction conditions were identical to those described above except TaqStart the phenotype of input cells, four CB samples each were Cell sorting. Staining of CD34-selected fractions was performed fractionated by double immunomagnetic selection and the as described above using anti-hu: CD34-PE, CD19-FITC, and either resulting populations (Control CB fractions in Table 1 ) were CD2-FITC or CD3-FITC. Cells were sorted aseptically into CD34 / CD19 0 /2 0 (3 0 ) and CD34 / CD19 / /2 / (3 / ) fractions with a Coulter used to assess the frequency of cells bearing the surface EPICS 752 flow cytometer using a Cicero acquisition system and markers subsequently measured in output cells from the ex-Cyclops software (Cytomation, Ft Collins, CO). periments. Antibody combinations and flow gating used for CFU assay. Input cells, as well as BM cells from experimental analysis were identical to those used for experimental output mice at the time of death, were placed into a CFU assay. The number cells. CD34 / cell purity ranged from 75% to 95% in control of mouse BM cells plated ranged from 1.47 to 3.57 1 10 5 /plate, fractions ( Table 1) . Purities of CD34 / fractions used in transdepending on the human cell content. One-milliliter aliquots of a plant experiments fell within this range or were above it mixture containing (vol/vol): 44% methylcellulose (Terry Fox Labo- (Table 1 ). Table 1 shows that myeloid progenitor cells ratories, Vancouver, BC), 30% FBS, 10% BSA, 1% 0.1 mmol/L (CD33 / ) comprised a consistent, albeit low, percentage of methylprednisolone, 1% 11 mmol/L b-mercaptoethanol, and 14% CD34 fractions, while more mature myeloid cells (CD13 / IMDM containing the appropriate number of cells, plus 1 U/mL human erythropoietin, 10 ng/mL each of human: IL-3, GM-CSF, and CD14 / ) were largely absent. Development from CD34 / and SCF (Amgen, Inc) were plated in quadruplicate into 30 cm 2 cells into the myeloid lineages could thus be detected in mice dishes (Falcon 1008; Becton Dickinson, Lincoln Park, NJ) as preusing these fractions. Erythroid progenitor cells (glycophorin viously described. 32 After 14 to 15 days at 37ЊC, the plates were A / CD71 / CD45 0 ) were present as well and ranged from scored for colony forming cells that included granulocyte/monocyte 0.15% to 3.8% of the fractions. The major contaminants in Table 1) pended in 25 mL 0.11 PBS in PCR tubes. The tubes were heated to 95ЊC for 8 minutes in a thermocycler. One mL proteinase K (20 by FACS. 
Abbreviation: ND, not determined. * Cell populations in CB fractionated by double immunomagnetic selection. † Cell populations in fractionated CB used to engraft mice. ‡ Cells were fractionated by one round of immunomagnetic selection followed by FACS for the CD34 / CD19 0 /2 0 (3 0 ) fraction.
and PB of all recipients. The fraction of human cells in these 2.75 1 10 4 CD34 / cells (experiment 8) were capable of organs ranged from 1% to 30% and was always lower than yielding detectable engraftment levels. that detected in BM. In two mice (from experiments 1 and
Conditions were assessed that affected engraftment of 3), the thymus was found to contain human cells exclusively.
CD34 fractions into recipients such as the pretreatment radia-It should be stressed that repopulation of mice thymi with tion dose and the need for administration of human growth human cells was not a consistent finding, but rather, a rare factors. Initial experiments were performed by irradiating event. Although a limiting dilution experiment was not permice with 400 cGy. At this dose 65% (26 of 40; experiments formed, the level of engraftment generally fell off with de-1, 3, and 7) of the animals died 1 to 2 weeks posttransplant. creasing numbers of input cells (Fig 1) . However, as few as Surviving mice generally engrafted well, however acute deaths, most likely due to radiation-induced toxicity, were considered too extreme. In experiments where mice received 350 (experiments 2 and 4 through 6) or 375 (experiment 8) cGy, engraftment levels were slightly lower than in mice that had received higher doses, but the number of early deaths was dramatically reduced to 20% (eight of 40). For later experiments, 350 cGy was used routinely for pretreatment.
In previous studies, consistent engraftment and development of CD34 / cells has relied on the influence of human growth factors. 15, 16 Alternatively, unfractionated CB (comprised of cells known to produce growth factors) has been shown to engraft mice to comparable levels with and without growth factor supplements. 21 Two experiments were performed (1 and 2) to assess the influence of human: IL-3, GM-CSF, and SCF supplied three times per week on engraftment and subsequent development of CD34 fractions. Figure 1 illustrates that engraftment levels in mice that received no growth factor treatments (open circles) were comparable to those in mice that received growth factors (closed circles). Additionally, significant differences were not detected in output human cell subpopulations between treated and untreated animals (Fig 2 and see below) . Because of these findings, subsequent experiments were done without the use of growth factors. tively. The cellularity of the tissues in all recipients was AID Blood 0030 / 5h38$$$581 08-14-97 10:29:10 blda WBS: Blood
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From normal. At the levels of engraftment obtained (Fig 1) , a from input CD34 / populations. Cells within the huCD45 gate were quantified for myeloid, lymphoid, and erythroid significant expansion of human cells in the mice occurred over the course of the experiments. For instance, the BM cell surface markers, as well as for the retention/expansion of a CD34 / population. Figure 3A shows representative anal-(from two femurs and two tibia) of an individual mouse in experiment 4 contained 3.25 1 10 7 cells, of which 30% were ysis of BM, spleen, and PB, while Fig 2 summarizes the values of each huCD45 / subfraction for all samples analyzed human. Thus, 9.75 1 10 6 human cells in the femurs and tibia were derived from 1 1 10 5 input cells, representing an in experiments 1 through 8. The myeloid component of BM ranged from 5% to 57% of the human population. CD13 / increase of at least 500-fold (the femurs and tibia represent only 20% of the BM cavity 35 ). In general, increases of human and CD13 / /33 / cells made up the majority of these populations, while CD14 / cells comprised a smaller proportion of cell numbers were observed in all mice, indicating that the mouse environment was conducive to proliferation of human huCD45 / cells. The fraction of myeloid cells in the huCD45 / gate varied between experiments, as well as be-hematopoietic cells.
Cells from the tissues were further analyzed by three-color tween individuals within experiments. B cells were the major human component of BM, in most cases, comprising 8.4% flow cytometry for evidence of multilineage development AID Blood 0030 / 5h38$$$581 08-14-97 10:29:10 blda WBS: Blood
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Fig 3. Development of human CD34 " cells in the hematopoietic tissues of NOD/SCID mice. (A) Typical profiles of human progenitor cell (CD34, CD33), myeloid cell (CD13, CD14), B-cell (CD19), and T-cell (CD2) surface markers on
huCD45 " output cells from the BM, spleen, and PB of repopulated mice. Cells in the glycophorin A " gate were 100% huCD71 " and 0% to 3% huCD45 " . Quantification of the CD34 " population was done by using a four parameter gating method. 31 (B) In the rare cases where huCD45 " cells populated the thymus (two mice), the vast majority (98%) were huCD2 " (upper histogram).
When the thymic population was gated on huCD3 " cells (which comprised 72% of the total cells), 95% were hu CD4/CD8 double positive cells (lower histogram).
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For personal use only. on October 31, 2017. by guest www.bloodjournal.org From to 85% of the huCD45 / cell population. Erythroid progeni-CD14 / cells ranged from 2.6% to 8.4%, and CD34 / cells comprised 2% to 18.6% of the huCD45 / population. Impor-tors were consistently found in low frequencies. BM from the majority of mice analyzed contained a substantial propor-tantly, CD19 / cells were the major population of human cells in the BM, spleen, and PB of all animals (Fig 4) . In tion of CD34 / cells. The proportion of CD34 / cells did not depend on the duration of the graft. Mice analyzed at 6 BM, CD19 / cells accounted for 28% to 62% of the human leukocytes. These cells were derived in the mice from SRCs weeks had 1.5% to 6.3% CD34 / cells, while mice analyzed at 15 weeks retained 2.5% to 6.9% CD34 / cells in their within a CD34 fraction containing cells with no detectable expression of CD19, suggesting that cells in this system can BMs.
Figures 2 and 3A reveal that CD13 / and CD14 / myeloid differentiate down the lymphoid pathway from CD34 / cells devoid of an early B-cell surface marker. cells were consistently found in the spleen and in the peripheral circulation of recipients, albeit generally at lower levels The huCD19 / populations of BM, spleen, and PB were analyzed for cell surface expression of hu IgM as evidence of than that seen in BM. Much lower proportions of myeloid cells were found in the spleen than in PB. As in BM, a further B-cell development. For this analysis, human CD45 / BM, spleen, and PB cells from repopulated mice were greater proportion of huCD45 / cells expressed CD13 than CD14, while the majority of cells expressed CD19 (Figs 2 stained with both anti-hu CD19 and anti-hu IgM. Human CD45 / cells from the lymph gate of the light scatter profile and 3A). It should be noted that the myeloid compartment seen in these organs consisted of CD13 / and CD14 / cells are shown in Fig 5. Without exception, all mice analyzed showed similar patterns of expression in the three hemato-and generally lacked the CD33 / and CD13 / /33 / populations that were found in BM (compare histograms in Fig 3A) . poietic compartments. This included mice that had been transplanted with CD34 / CD19 0 cells from experiments 5 Erythroid progenitors were found in over half of the spleens analyzed and were generally low in frequency. Erythroid and 8 where both more mature CD19 / cells, as well as CD34 / CD19 / pro B cells were absent from the input cell progenitors were not detected in PB. CD34 / progenitor cells were consistently found in spleen at lower frequencies than fraction ( Table 1 ). In the BM, the majority of CD19 / cells expressed no cell surface IgM; a finding that would be ex-in BM. Again, no CD34 / cells were detected in PB samples (Figs 2 and 3A ). Figure 2 also shows that there were no pected in a primary lymphopoietic site. In contrast to the BM, approximately two thirds of the CD19 / cells in the significant differences in subpopulation distributions found in BM, spleen, or PB samples between mice supplemented spleen expressed IgM, indicating a more mature B-cell population. In PB, 75% to 90% of the CD19 / population ex-with human growth factors and those that were not (experiments 1 and 2).
pressed IgM. These findings suggest that human B-cell maturation in mice is correlated with a progression of cells from A grossly visible thymus was usually absent from mice at the time of killing. In mice where the thymus was seen, the site of primary lymphopoiesis, the BM, to the peripheral circulation, similar to the situation in humans. it was collected and analyzed. Most contained mouse CD45 / cells exclusively that were probably a prelude to thymoma, Colony-forming potential in vitro. As a further indication of human myelopoiesis, the human hematopoietic colony-form-which develops in these mice after 5 to 7 months of life. 23 However, two mice (one each from experiments 1 and 3)
ing potential was determined for output cells from the BMs of repopulated mice. The CFU assay was performed on output had a thymus that contained 1 to 2 1 10 7 cells that were 91% to 96% huCD45 / . Within this population, 98% of the cells from mice in all experiments. BM from all mice exhibited the same levels of output cell colony-forming potential relative cells were CD2 / (Fig 3B, top histogram) . When cells in this population were stained with anti-hu: CD3, CD4, and CD8, to that of input cells, including those mice that were treated with human growth factors. Data from experiment 4 are presented in it was found that the majority (95%) were CD3 / /CD4 / / CD8 / (Fig 3B, bottom histogram) . Input cells consistently Fig 6 as representative. A substantial number of CFUs, that included CFU-GM, BFU-E, and CFU-GEMM, were found in were contaminated with a CD2 / population ( Table 1) . However, analysis of two CD34 / input cell fractions showed the the BMs of all mice analyzed (Fig 6, open circles) . Values for total CFUs were calculated by multiplying the number of CFUs presence of no CD4/CD8 (double positive) cells, suggesting the human T cells found in these thymi represent de novo counted by the fraction of total huCD45 / cells/huCD45 / cells plated for both input cells and output cells from each mouse. lymphopoiesis in the mouse thymic environment. The basis for the inconsistent nature of thymic colonization by human Figure 6 (closed circles) reveals that the total colonies derived from 1 1 10 5 input cells included 2.09 1 10 3 CFU-GM, 5.88 CD34 / cells remains to be determined.
As lymphoid cells were a consistent contaminant of input 1 10 3 BFU-E, and 30 CFU-GEMM. Total output cell CFUs were calculated for BMs of five mice (range of huCD45 / cell cell CD34 fractions, the CD19 / cells observed in mouse hematopoietic tissues might have been due to expansion of populations, 14% to 34%) 10 weeks postinfusion of 1 1 10 5 input cells and included (mean { standard error [SE]): 1.6 1 cells already committed to the B-cell lineage. To determine if CD19 / cells were indeed generated from more immature 10 4 { 3.4 1 10 3 CFU-GM, 2.08 1 10 4 { 3.05 1 10 3 BFU-E, and 176 { 29 CFU-GEMM (Fig 6, open circles) . These are precursors, CD19 / cells were removed from CD34 fractions by FACS before infusion into mice (experiments 5 and 8).
the minimum number of human CFUs derived from the mice; cells capable of producing myeloid colonies that were not taken Analysis of these experiments showed that myeloid, lymphoid, erythroid, and progenitor cell levels in BM, into account included the BM fraction excluded from the femurs and tibia and the spleen cell population. spleen, and PB fell within the range of values seen in the other experiments. CD13 / /33 / cells made up 6% to 26%.
To confirm that the colonies grown in the CFU assay were AID Blood 0030 / 5h38$$$581 08-14-97 10:29:10 blda WBS: Blood
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From of human origin, all GEMM colonies, as well as 30 GM and modal proportions and using 100% as the estimated proportion and analysis of at least 60 colonies/mouse, the confi-30 BFU-E colonies (representing 3.5% to 10.6% and 5.4% to 8.4% of the total GM and BFU-E colonies, respectively, dence level is 95% that from 94% to 100% of the colonies from each mouse were human. These results strongly suggest derived from each mouse) were plucked from CFU plates of each mouse and analyzed by a human-specific PCR (Fig  that only human colonies were able to proliferate under the conditions used in this CFU assay. 6). While DNA extracted from untransplanted, control mouse BM cells showed no amplified product, every colony Taken together, these data suggest that substantial human myelopoiesis and erythropoiesis occurs in mouse BM as analyzed from output cell CFU plates produced a product of the same size as one amplified from human white blood demonstrated by the significant number of human colonyforming cells identified. cells (É150 bp; Fig 6) . Using an exact nomagram for bi- Fig 5. B-cell development. In the BM of mice from all experiments only 10% to 20% of huCD19 " cells expressed cell surface IgM. In the spleen 60% to 75% of CD19 " cells also expressed IgM. PB from all mice revealed that 75% to 90% of huCD19 " cells also expressed IgM. This was true for mice transplanted with input CD34 " cell fractions known to be contaminated with low levels of CD19 " cells (experiments 4 and 7, Table 1 ), as well as for mice transplanted with CD34 " input fractions devoid of any CD19 " cells (experiments 5 and 8, Table 1 ).
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For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Fig 6. Human myeloid colony-producing potential in vitro of input cell fractions and of output cells from the BMs of repopulated mice. Total GM, erythroid (BFU-E), and GEMM colonies are plotted for 1 Ì 10 5 input cells from experiment 4 (q). BM cells from five mice that had each been infused with 1 Ì 10 5 input cells and allowed to engraft for 10 weeks were plated into the CFU assay. The means and SE of the total CFU in each category are plotted (᭺). All colonies analyzed by a human-specific PCR (at least 30 colonies/CFU type/mouse) were of human origin. Typical PCR signals are shown below specific colony types for human Cart-1 (lanes 6, 8, and 10) and for b-actin (lanes 7, 9, and 11 ). Controls consisted of PCRs for human Cart-1 (lanes 2 and 4) 4 and 5) . Lane 1 shows a 123-bp ladder. The predicted amplified products for the hu Cart-1 PCR and for the bactin PCR are 156 and 249 bp, respectively. Secondary transplants. As phenotypic analysis of pri-expressed CD14, and no CD34 / cells were detected (not shown). Human CD45 / cells in the PB consisted of CD13 / mary recipients indicated maintenance of a human CD34 / population, the next series of experiments was aimed at de-(13%), CD14 / (5.7%), and CD19 / (61%) populations (not shown). SRCs in the original CD34-enriched fraction, there-termining whether the human cell fraction contained SRC with the capacity for more durable, multilineage en-fore, were capable of sequentially repopulating two mice with myeloid, lymphoid, and progenitor cells over a total graftment. In these experiments, we evaluated the ability of BM from previously engrafted mice to repopulate secondary period of 4 months. Both mice transplanted with mouse BM from experiment recipients with human cells. BM of one mouse from experiment 1 (83% huCD45 / after 8 weeks) was transplanted into 7 survived and were analyzed 9 weeks posttransplant. BMs from the mice contained 10% and 6% huCD45 / cells, re-three recipients (calculated human CD34 / cells received/ mouse was 6.8 1 10 5 ) and BM of a second mouse, from spectively, while spleens and PBs from both mice contained 1% to 2% huCD45 / cells. Subpopulation analysis of experiment 7 (51% huCD45 / after 15 weeks), was transplanted into two recipients (calculated human CD34 / cells huCD45 / cells showed results similar to those described above. To date, the original CD34-enriched fraction has been received/mouse was 2.1 1 10 5 ). Two of the three mice from the first transplant died 7 and a half weeks posttransplant, capable of engrafting and developing in mice for 4 months while maintaining cells able to repopulate secondary recipi-however significant human engraftment was found in the BM and periphery of the remaining mouse 8 weeks post-ents for an additional 2 months, resulting in a total engraftment time of 6 months. Although only a limited number transplant. Human CD45 / cells comprised 23% of BM cells, 5% of spleen cells, and 5.5% of PB cells in this mouse ( Fig  of secondary recipients have been analyzed, these data suggest that cells maintained in primary recipients did retain 7A). Within the huCD45 / gate of the BM the levels of developing progenitor, myeloid and lymphoid cells paral-some repopulation capacity. leled those seen in primary transplants. Specifically, 23% DISCUSSION expressed CD13/33, 8% expressed CD14, 63% expressed CD19, and 5.5% expressed CD34 ( Fig 7B) . Thus, a CD34 / Evidence presented in this report establishes that CD34enriched cells derived from human CB and infused intrave-population was maintained at levels equal to those in primary recipients. In the spleen, the majority of huCD45 / cells ex-nously consistently engraft NOD/SCID recipients. Over 90% of recipients that survived to the end of the experimental pressed CD19 (80%), while 8% expressed CD13/33, 4% AID Blood 0030 / 5h38$$$581 08-14-97 10:29:10 blda WBS: Blood period showed varying degrees of human cell repopulation.
and b-actin (lanes 3 and 5) from human PB leukocytes (lanes 2 and 3) and normal mouse BM cells (lanes
of CB progenitors, as well as the output cell subpopulation distributions and colony-forming potential, were largely un-As in human hematopoietic progenitor cell transplants, BM was the primary site of repopulation, but peripheral hemato-affected by the influence of human IL-3, GM-CSF, and SCF. Previous studies have shown that unfractionated CB can poietic organs showed significant repopulation with human cells as well. This is the first report showing that the CD34 / engraft without the addition of exogenous growth factors. 21 However, this population contains cell types (eg, T cells) progenitor cell fraction of human CB can engraft and proliferate throughout the hematopoietic tissues of NOD/SCID that could be producing growth factors in vivo. This is the first report in a mouse xenotransplant system where human recipients.
For mice to survive in reasonable numbers following suc-hematopoietic development has been seen from CD34 / progenitor cells without growth factor supplementation. This is cessful engraftment, the pretreatment radiation dose was crucial. At 400 cGy, 65% of recipients died within the first 2 significant because high levels of human growth factors are not normally found systemically and could alter the en-weeks following radiation treatment. This is perhaps not surprising, as the SCID mutation is known to confer high graftment potential of the input cell population. This data also suggests that cells contained in the CD34 / CB popula-radiation sensitivity to the animals. 36, 37 However, at a dose of 350 cGy, only É15% of the mice died acutely following tion possess an intrinsic ability for engraftment. Alternatively, or perhaps in addition, the NOD/SCID stroma may irradiation. While at the higher radiation dose, surviving mice generally showed the highest levels of engraftment (5% be a particularly favorable environment for supporting engraftment of these cells. 38 The fact that growth factor supple-to 95%), levels found at the lower radiation dose, where huCD45 / cells in the BM generally ranged from 10% to ments are not required for engraftment, development, and proliferation of CD34 / cells may be advantageous for future 60%, were adequate for the developmental analysis of human cells. studies in determining the in vivo developmental potential of rare human progenitor cell populations without the bias In other mutant mouse models, human growth factor supplements were required to obtain substantial proliferation of that specific growth factors may introduce. The human CD34 / cells infused into mice did not transplanted human BM or PB cells. [14] [15] [16] [18] [19] [20] In this system, engraftment and development of CD34 / CB cells in the randomly distribute and proliferate throughout the mouse hematopoietic organs, but instead were partitioned in a man-absence of exogenous human growth factors was evident over the entire range of input cell doses used. In two of the ner consistent with normal hematopoiesis. Human CD34 / cells were found primarily in the mouse BM, as were the experiments (1 and 2), where input CD34 / cell doses were 5 1 10 5 and 3.5 1 10 5 , respectively, the level of engraftment most immature populations of B cells (predominantly AID Blood 0030 / 5h38$$$581 08-14-97 10:29:10 blda WBS: Blood CD19 / IgM 0 ) and myeloid cells (CD13 / /33 / ). In addition, Likewise, repopulating SRCs with the potential to home to and repopulate a secondary recipient are maintained in erythroid precursors were found primarily in the BM. In mouse PB, more mature populations of myeloid (CD13 / ) NOD/SCID mouse BM for at least 4 months. Engraftment levels in secondary recipients were not as high (range, 6% to and B cells were found (predominantly CD19 / IgM / ), while no populations of CD34 / cells or of erythroid progenitors 23% in BMs) as those generally found in primary recipients, however, this may be explained by the fact that human cells were detected. This finding suggests not only that mouse BM was the primary site of human hematopoiesis, but that in the input fraction had to compete with normal mouse BM cells for available sites in the recipients' BM. Engrafted cells capable of engrafting mice in the original input CD34 fraction homed to the mouse marrow. Human CD34 / cells, human cells were once again capable of producing myeloid and lymphoid populations, as well as sustaining a CD34 / at least to some extent, must recognize and adhere to the appropriate environment in the mouse BM, suggesting that population for the duration of the experiments (an additional 2 months). In an elegant experiment, Nolta et al 16 genetically this homing mechanism may be conserved between these species. Moreover, it appears that the developmental pro-marked input human CD34 / cells derived from BM and PB and showed that BNX mice retained multilineage repopulat-gression of human progenitor cells to more mature, lineagedefined cells proceeds normally from the NOD/SCID mouse ing cells for up to 10.5 months. In the present experiments, we show that repopulating SRCs from CB, contained in the BM to the peripheral hematopoietic tissues.
A novel finding in this study was that B cells could de-CD34 / cell fraction, are maintained in NOD/SCID marrow and retain their capacity to home to a second marrow follow-velop in mice from a CD34-enriched fraction that had been purged of CD19 / cells before transplanting. Whereas it could ing serial transplantation. These results suggest that the NOD/SCID model may be a useful assay for long-term re-be argued that myeloid development may have occurred from committed progenitor cells (input fractions were con-populating cells contained in rare cell populations. taminated with low levels of CD33 / cells), this data suggests ACKNOWLEDGMENT that immature B cells developed de novo in the BM from CD34 / input cells. Analysis also revealed that CD19 / cells We gratefully acknowledge the invaluable assistance of Karen comprised a comparable fraction of huCD45 / cells in mouse Helm for cell sorting and consultation on flow cytometric analysis. tissues to that found in mice transplanted with unpurged We would also like to thank Doreen Jumbeck of the National Jewish Center Biological Resource Center for excellent care and monitoring CD34 / fractions. Furthermore, in all experiments, B cells of experimental animals. Finally we thank Drs David Gordon and were found to mature as they moved from the BM to the Bill Wood for providing human-specific primer sequences for the peripheral circulation. While CD19 / cells in BM were Cart-1 gene in advance of publication and Dr Ralph Quinones for É75% to 85% negative for expression of surface IgM, those comments on the manuscript. found in PB were 75% to 90% positive for expression of IgM. This shows that NOD/SCID mice are able to support more refined definition of the SRC. AID Blood 0030 / 5h38$$$581 08-14-97 10:29:10 blda WBS: Blood
